Q4 & Full Year 2025 Financial Results As of December 31, 2025, reported on March 12, 2026 NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 1 Safe Harbor Statements This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently ...

Core Insights - The Joint Corp. reported a 3.1% increase in fourth quarter revenues year over year, with full year revenues reaching $54.9 million and net income of $2.9 million, alongside a 13.9% increase in Adjusted EBITDA to $13.0 million [1][15][16]. Financial Performance - Fourth quarter revenues were $15.2 million, up from $14.7 million in the same quarter of 2024 [9]. - System-wide sales for the year were $532.4 million, a slight increase of 0.4%, while comparable sales declined by 0.4% compared to a 3.9% increase in 2024 [8][15]. - The company improved net income from consolidated operations to $1.0 million, compared to $18,000 in the fourth quarter of 2024 [11]. - Adjusted EBITDA from consolidated operations increased by 7.8% to $3.6 million, while Adjusted EBITDA from continuing operations was $1.6 million, down from $2.0 million in the fourth quarter of 2024 [12][16]. Refranchising and Operational Strategy - The company is advancing its Joint 2.0 transformation strategy, aiming to become a pure-play franchisor by refranchising 41 clinics and currently working on 27 more [3]. - Operational discipline is being implemented to enhance operating leverage, contributing to year-over-year Adjusted EBITDA improvements despite macroeconomic challenges [3][5]. - The company has shifted its marketing strategy to enhance brand awareness, resulting in improved patient attrition rates and faster breakeven for new clinic openings [4]. Share Repurchase and Capital Allocation - In 2025, the company repurchased 1.3 million shares for a total of $11.3 million as part of its capital allocation strategy [5][14]. - The company maintains a $20 million undrawn line of credit with JP Morgan Chase, providing financial flexibility [13]. Future Guidance - For 2026, the company expects system-wide sales to be between $519 million and $552 million, with comparable sales projected to range from -3% to 3% [20]. - Consolidated Adjusted EBITDA is anticipated to be between $12.5 million and $13.5 million, with new franchised clinic openings expected to be between 30 and 35 [20].

Core Viewpoint - The Joint Corp. has announced a stock repurchase program of up to $5 million, reflecting the board's confidence in the company's long-term strategy and projected cash flow generation [1][2]. Company Overview - The Joint Corp. is the largest provider of chiropractic care in the U.S. through The Joint Chiropractic network, with over 950 locations and more than 14 million patient visits annually [3]. - The company operates a retail healthcare business model that eliminates the need for insurance, making chiropractic care more accessible and affordable [3]. - The Joint Corp. has received multiple accolades, including being named "No. 1 in Chiropractic Services" by Entrepreneur and consistently ranking in Franchise Times' annual lists [3]. Business Structure - The Joint Corp. functions as both a franchisor and operator of clinics in various states, providing management services to affiliated chiropractic practices [4]. Stock Repurchase Program Details - The stock repurchase program is set to begin in August 2025 and will have a termination date of June 3, 2027. The program allows for repurchases through various means, subject to market conditions [2]. - The finance committee of the board will determine the timing, number, and amount of repurchases at its discretion [2].

Core Insights - The Joint Corp. reported a 7% increase in revenue from continuing operations, reaching $13.1 million in Q1 2025 compared to $12.2 million in Q1 2024, driven by a greater number of franchised clinics [7][8] - System-wide sales increased by 5% to $132.6 million, indicating economic resilience [8] - The company experienced a net loss from continuing operations of $506,000, compared to a loss of $399,000 in the same quarter of the previous year [11] Financial Performance - Adjusted EBITDA for continuing operations was $46,394, down from $424,708 in Q1 2024 [12][37] - Selling and marketing expenses rose to $3.5 million from $2.2 million in Q1 2024, reflecting the costs associated with transitioning to a new marketing team [8][10] - The cost of revenue increased to $3.0 million from $2.7 million, attributed to higher regional developer royalties and commissions [7] Operational Highlights - The company sold 9 franchise licenses in Q1 2025, a decrease from 15 in Q1 2024, due to the refranchising process [9] - Five new franchised clinics were opened, while two corporate clinics were refranchised and one was closed, bringing the total clinic count to 969 [9] - The company aims to enhance its digital marketing and patient experience to drive growth in new clinic openings and system-wide sales [5] Guidance and Future Outlook - The company expects system-wide sales to be between $550 million and $570 million for 2025, compared to $530.3 million in 2024 [19] - Comp sales for clinics open for 13 months or more are projected to be in the mid-single digits, up from 4% in 2024 [19] - Consolidated Adjusted EBITDA is anticipated to be between $10.0 million and $11.5 million, compared to $11.4 million in 2024 [19]

Financial Data and Key Metrics Changes - System wide sales increased to $530.3 million, up 9% in Q4 2024 compared to 8% in Q3 2024 [15] - Revenue for continuing operations increased 14% in Q4 2024, up from 10% in Q3 2024 [16] - Consolidated adjusted EBITDA was $3.3 million for Q4 2024 and $11.4 million for the full year 2024 [17][34] Business Line Data and Key Metrics Changes - System wide comp sales for all clinics opened for thirteen months were 6% in Q4 2024, up from 4% in Q3 2024 [15] - System wide comp sales for mature clinics opened for 48 months were modestly positive for Q4 2024, improving from negative 2% in Q3 2024 [15][26] - Revenue from franchise operations reached $14.4 million in Q4 2024, compared to $12.7 million in Q4 2023, reflecting a 14% increase [29] Market Data and Key Metrics Changes - The company served approximately 950,000 new patients in 2024, with 36% of them being new to chiropractic care [10][25] - The annual spending on chiropractic care is estimated at $20.6 billion, with out-of-pocket spending increasing from 37% to 42% [37] Company Strategy and Development Direction - The company aims to strengthen its position as a leading chiropractic care provider and become a pure play franchisor [9][12] - Plans include refranchising to reduce overhead and increase operating leverage, with a focus on dynamic revenue management and enhancing digital marketing [18][21] - The company is exploring new revenue streams, including B2B opportunities and additional clinical services [19][86] Management Comments on Operating Environment and Future Outlook - Management noted that consumer behavior is being affected by stubborn inflation and economic uncertainty, impacting patient demographics [47][48] - The company expects 2025 to be a transition year as it shifts from corporate-owned clinics to a franchise model, which will enhance profitability [35][90] - Management is focused on reducing G&A expenses to improve the bottom line significantly in the coming years [29][92] Other Important Information - The company opened 57 franchise clinics in 2024 and closed 18, resulting in a total of 967 clinics, with 87% being franchise clinics [27] - The company has received accolades, including being recognized as number 38 on the Fast and Serious 2025 list of the smartest growing franchises [44] Q&A Session Summary Question: Comments on potentially slower consumer behavior in Q1 metrics - Management acknowledged signs of consumer response to inflation and economic uncertainty, particularly affecting their target demographic [47][48] Question: Retention rates and trends - Retention rates remained stable, with strong conversion rates for new patients and slight upticks in attrition typical for January [51][53] Question: Status of refranchising efforts - The company has 125 corporate clinics, with the majority under LOI negotiations, aiming to complete refranchising in the first half of the year [55][80] Question: Trends in same store sales - Year-to-date trends are consistent with Q4 figures, with expectations for Q1 to align with previous trends [60][61] Question: Valuation of LOIs for refranchising - Management indicated that bidders are looking at a multiple of EBITDA for the corporate clinics, with ongoing negotiations [62][64] Question: Customer acquisition costs and revenue growth - Increased marketing spend is aimed at driving new patient acquisition, with a focus on optimizing customer acquisition costs [66][68] Question: Pricing strategy and legacy customer rates - The last wholesale price increase occurred in March 2022, with 80% of active members on standard rates and 20% on legacy rates [72][74] Question: Timing for new services and retail products - Exploration of new services and retail products is ongoing, with a focus on strengthening core operations before launching new initiatives [86]